Tulane University School of Medicine

US Health Officials Urge Vaccination Against Flu, COVID-19, and RSV This Fall and Winter

Retrieved on: 
Thursday, September 28, 2023
Vaccine, United Nations Foundation, Infection, National Foundation for Infectious Diseases, Tulane University School of Medicine, Pregnancy, Streptococcus, Hopkins, Diabetes, Education, Vaccination, Hospital, COVID-19, Woman, Medicine, Pharmacy, Doctor of Philosophy, MS, CDC, Death, CPNP, RSV, Mask, Risk, Patient, Korea Disease Control and Prevention Agency, Brace, Immune system, Schaffner, RN, Health, Cardiology, MPH, White, News, Kidney disease, NFID, Pharmaceutical industry, MD

BETHESDA, Md., Sept. 28, 2023 /PRNewswire/ -- As the US braces for the upcoming fall and winter virus season, new survey data released today by the National Foundation for Infectious Diseases (NFID) show that despite the potential severity, only 22% of US adults are worried about themselves or someone in their family getting infected with influenza (flu), with similar low levels of concern about COVID-19 (23%) and respiratory syncytial virus (RSV) (19%) infection. The data also show that although nearly two-thirds of US adults (65%) agree that vaccination is the best preventive measure against flu-related hospitalizations and deaths, 43% of US adults do not plan to or are unsure if they will get vaccinated against flu. Although updated COVID-19 vaccines are recommended, only 40% plan to get vaccinated against COVID-19, and among adults age 60 years and older, only 40% plan to get vaccinated against RSV.

Key Points: 
  • We must use all available tools to protect those most at risk, including infants and young children, pregnant people, older adults, and those with chronic health conditions."
  • "The NFID data—which show complacency around vaccination against flu, COVID-19, RSV, and pneumococcal disease—are concerning," said NFID President Patricia (Patsy) A. Stinchfield, RN, MS, CPNP.
  • "Even in cases when vaccination does not prevent infection entirely, getting vaccinated can help protect against serious complications, including hospitalization and death."
  • "Flu season is a great time to ask about pneumococcal vaccination because pneumococcal disease can be a serious complication of flu."

SkinMD Dermatology & Skin Enhancement Center Joins Epiphany Dermatology

Retrieved on: 
Tuesday, September 26, 2023
General Health, Other Health, Hospitals, Health, Practice Management, Tulane University School of Medicine, Partnership, Skin care, Marketing, Skin, Dermatology, Walter Reed Army Medical Center neglect scandal, Patient, Entrepreneurship, Nursing, Hospital, Epiphany

Epiphany Dermatology, a leading dermatology company committed to improving access to exceptional dermatologic care, announced today it has expanded its presence in Colorado through its partnership with Dr. Elizabeth Piantanida, and her team at SkinMD Dermatology & Skin Enhancement Center, based in Colorado Springs.

Key Points: 
  • Epiphany Dermatology, a leading dermatology company committed to improving access to exceptional dermatologic care, announced today it has expanded its presence in Colorado through its partnership with Dr. Elizabeth Piantanida, and her team at SkinMD Dermatology & Skin Enhancement Center, based in Colorado Springs.
  • Founded in 2013 by Dr. Elizabeth Piantanida, SkinMD Dermatology & Skin Enhancement Center has a solid reputation of providing individualized and high-quality dermatologic care and cosmetic services to patients in the greater Colorado Springs marketplace.
  • Dr. Piantanida commented, “My staff and I are excited to join Epiphany Dermatology.
  • Epiphany also benefits from the clinical expertise of SkinMD Dermatology & Skin Enhancement Center’s team, as best practices are collaboratively shared across the Epiphany network.

Parexel’s Amy McKee, M.D. Named to 2023 PharmaVoice 100

Retrieved on: 
Wednesday, September 20, 2023
Tulane University School of Medicine, BioCryst Pharmaceuticals, Parexel, Science, Medicine, Patient, Oklahoma Office of the Chief Medical Examiner, Neuroscience, Pleasure, FDA, Vaccine, Industry Dive, ChromeOS, Pharmaceutical industry, Hematology

During her tenure at Parexel she has been instrumental in providing patient-led medical and scientific expertise in support of the company’s therapeutic and regulatory strategies.

Key Points: 
  • During her tenure at Parexel she has been instrumental in providing patient-led medical and scientific expertise in support of the company’s therapeutic and regulatory strategies.
  • Since its inception in 2005, the PharmaVoice 100 highlights outstanding individuals across the industry who serve as sources of inspiration to their teams, companies and communities.
  • Each honoree of the PharmaVoice 100 has been nominated and selected based on substantive personal accounts describing how they have profoundly motivated and inspired their colleagues and peers in their respective fields.
  • To view the full list of PharmaVoice 100 honorees, click here .

C2N Diagnostics Releases the PrecivityAD2™ Blood Test for Clinical Care, a Robust Assay with High Concordance to Amyloid PET and CSF

Retrieved on: 
Thursday, August 17, 2023
Mental Health, Research, Clinical Trials, Biotechnology, Other Health, Health, General Health, Other Science, Science, Lund University, Laboratory developed test, Tulane University School of Medicine, LDT, Diagnosis, Chronic kidney disease, APS2, Cardiovascular disease, Pathology, Deficit spending, PET, Brain, Biomarker, Approximation error, Dementia, Amyloid, Plasma, Patient, C2N, Blood, AUC, Neurology, CSF, Ageing, AD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Conference, FAAN, Food, Disease, Medical device, Medical imaging

C2N Diagnostics , a leader in advanced brain health diagnostics, today announced the release of the PrecivityAD2 blood test , a clinical care assay that meets the standard of care with currently available PET scans and cerebrospinal fluid tests.

Key Points: 
  • C2N Diagnostics , a leader in advanced brain health diagnostics, today announced the release of the PrecivityAD2 blood test , a clinical care assay that meets the standard of care with currently available PET scans and cerebrospinal fluid tests.
  • In a clinical validation study involving two independent cohorts totaling 583 patients with cognitive impairment using amyloid PET as the reference standard, the PrecivityAD2 blood test achieved an overall test performance statistic of 0.94 AUC and 88% accuracy.
  • The PrecivityAD2 blood test simultaneously quantifies specific plasma amyloid beta and tau peptide concentrations to calculate the Aβ42/40 Ratio and p-tau217/np-tau217(p-tau217 Ratio).
  • In this regard, the PrecivityAD2 blood test makes a significant contribution to the diagnosis of patients with Alzheimer’s disease.

SOPHiA GENETICS Reports Financial Results for the Second Quarter of Fiscal 2023

Retrieved on: 
Tuesday, August 8, 2023
Operating cost, White House, Tulane University School of Medicine, Eastern Time Zone, Education, Central European Summer Time, Marketing, NGS, COVID-19, Microsoft, H. Lee Moffitt Cancer Center & Research Institute, Research, COVID, Biomarker, History, Forecasting, White, Sophia, Constant, Sophia Genetics, Lila Tretikov, Blood, Memorial Sloan Kettering Cancer Center, GENETICS, Corporation, Cancer Moonshot, Artificial intelligence, Growth, Annual general meeting, Video game, Pharmaceutical industry, Wikimedia Foundation

Gross margin was 67% for the second quarter of 2023 compared with 65% for the second quarter of 2022.

Key Points: 
  • Gross margin was 67% for the second quarter of 2023 compared with 65% for the second quarter of 2022.
  • Adjusted gross margin was 70% for the second quarter of 2023 compared to 67% for the second quarter of 2022.
  • R&D expenses for the second quarter of 2023 were $8.9 million compared to $9.0 million for the second quarter of 2022.
  • Operating loss for the second quarter of 2023 was $20.0 million compared to $24.1 million in the second quarter of 2022.

Tulane University School of Medicine Uses SOPHiA GENETICS to Advance Research of Blood Cancers

Retrieved on: 
Tuesday, August 8, 2023
Lymphoma, Tulane University School of Medicine, Education, Face, Workflow, Tumors of the hematopoietic and lymphoid tissues, NGS, Bone marrow, Cancer, Research, Biomarker, History, Doctor of Philosophy, Sophia, Malignancy, Sophia Genetics, MD, Data, Blood, GENETICS, Medicine, Artificial intelligence, Multiple myeloma, Pharmaceutical industry

BOSTON and ROLLE, Switzerland, Aug. 8, 2023  /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that the Tulane University School of Medicine in New Orleans, Louisiana is live on SOPHiA GENETICS technology. The 15th oldest medical school in the United States, Tulane University School of Medicine has a longstanding history of medical research and education and will leverage the SOPHiA DDM™ Platform to help scale its hematologic (blood) testing program to advance blood cancer research.

Key Points: 
  • The 15th oldest medical school in the United States, Tulane University School of Medicine has a longstanding history of medical research and education and will leverage the SOPHiA DDM™ Platform to help scale its hematologic (blood) testing program to advance blood cancer research.
  • said Yuwen Li, MD, PhD, Director of Molecular Genetics Diagnostic Laboratory , Tulane University School of Medicine.
  • The SOPHiA DDM™ Platform will also enable Tulane University School of Medicine to retain custody of its samples and data.
  • "With the adoption of the SOPHiA GENETICS Platform, we are confident that Tulane University School of Medicine will be able to scale its program, further research of blood cancers, and efficiently increase the use of precision medicine."

Christine Hamori, MD, FACS, Named a Top Doctor by Castle Connolly

Retrieved on: 
Wednesday, July 26, 2023
Com, Tulane University School of Medicine, University, Patient, Private practice, Boston University, Medical device, Nursing

BOSTON, July 26, 2023 /PRNewswire-PRWeb/ -- Renowned plastic surgeon Christine A. Hamori, MD, FACS, has been honored as a Castle Connolly Top Doctor for the year 2023 in the area of cosmetic plastic surgery for the 15th year. The distinction reaffirms Dr. Hamori's commitment to surgical excellence and patient care and her exceptional contributions to women's intimate health and wellness.

Key Points: 
  • "I am grateful to be recognized as a Castle Connolly Top Doctor for 2023," said Dr. Hamori.
  • It's so rewarding to make a positive impact on people and to witness first-hand their renewed self-confidence."
  • For more information about Dr. Christine Hamori and her practice, please visit www.christinehamori.com .
  • Jean Sidoti, Christine Hamori Cosmetic Surgery + Skin Spa, 1 781-934-2200, [email protected] , https://www.christinehamori.

Pettit Kohn Welcomes Esteemed Attorney John E. Drazkowski to the Arizona Team

Retrieved on: 
Thursday, June 22, 2023
Tulane University School of Medicine, University, Business, Coif, Transport, Wharton School of the University of Pennsylvania, Order of the Coif, Hospital, Physician, Knowledge, Tulane University Law School, Chemical engineering, Insurance, PHOENIX, Counsel, Phoenix

PHOENIX, June 22, 2023 /PRNewswire-PRWeb/ -- Pettit Kohn Ingrassia Lutz & Dolin, a leading trial and civil litigation firm, is pleased to welcome John E. Drazkowski to its legal team. He joins the Transportation and Retail Law practice groups as Of Counsel in the Phoenix, Arizona office and strengthens the firm's capabilities in serving their clients' diverse legal needs.

Key Points: 
  • Pettit Kohn Ingrassia Lutz & Dolin, a leading civil and litigation law firm, welcomes Of Counsel John E. Drazkowski, Esq.
  • PHOENIX, June 22, 2023 /PRNewswire-PRWeb/ -- Pettit Kohn Ingrassia Lutz & Dolin, a leading trial and civil litigation firm, is pleased to welcome John E. Drazkowski to its legal team.
  • Mr. Drazkowski has spent nearly three decades practicing law and brings a wealth of knowledge and experience to Pettit Kohn.
  • He earned his Bachelor of Science degree in Chemical Engineering from the University of Arizona.

Janux Therapeutics Appoints Zachariah McIver, D.O., Ph.D., Vice President, Clinical Development

Retrieved on: 
Monday, June 5, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Glioma, Tulane University School of Medicine, Cleveland Clinic, GVHD, Osteopathic medicine in the United States, University, Next Generation Science Standards, CD28, PSMA, Physician, Ohio University College of Arts and Sciences, American Society of Clinical Oncology, National Heart, Lung, and Blood Institute, Clinical and Translational Science Award, Drug, Head, Breast, Toxicity, Prostate, American Society of Hematology, Immunotherapy, Lung, Neck, Colon, NHLBI, Heritage College of Osteopathic Medicine, Wake Forest, Colorectal cancer, EGFR, Hematology, Wake Forest University School of Law, Renal cell carcinoma, American College of Physicians, American College, Cleveland, Therapy, Society, NIH, PD-L1, National Institutes of Health Clinical Center, Bone marrow, Pharmaceutical industry, Vaccine, Molecular medicine, Physics

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Dr. Zachariah (“Zach”) McIver as Vice President, Clinical Development.

Key Points: 
  • Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Dr. Zachariah (“Zach”) McIver as Vice President, Clinical Development.
  • “Zach has extensive clinical research experience including leading the clinical development to maximize the value of bispecific T-cell engager assets across multiple hematologic and solid tumor malignancies,” said David Campbell, Ph.D., President and CEO of Janux Therapeutics.
  • “With TRACTr and TRACIr, Janux has built two very powerful platforms designed to overcome the toxicity and efficacy limitations of earlier generations of bispecific immunotherapies,” said Dr. McIver.
  • In addition to named programs, Janux is generating a number of unnamed TRACTr and TRACIr programs for potential future development.

The Chopin Law Firm Welcomes Experienced Trial Attorney Frankie Cannone to Its Growing Team

Retrieved on: 
Monday, May 1, 2023
Insurance, Tulane University School of Medicine, University, Professional, Lawyer, History of the University of Maryland, College Park, Ethics, Tulane University Law School, Personal injury, Practice of law, Risk management

NEW ORLEANS, May 1, 2023 /PRNewswire-PRWeb/ -- The Chopin Law Firm LLC, a prominent personal injury law firm in New Orleans, is pleased to announce the addition of attorney Frankie Cannone to its team of experienced lawyers. With over 100 years of combined experience and a commitment to providing effective legal solutions for their clients, The Chopin Law Firm welcomes Mr. Cannone's experience and expertise in personal injury and hurricane litigation.

Key Points: 
  • Frankie Cannone, a seasoned trial attorney, joins The Chopin Law Firm, bolstering their personal injury and hurricane litigation expertise.
  • NEW ORLEANS, May 1, 2023 /PRNewswire-PRWeb/ -- The Chopin Law Firm LLC, a prominent personal injury law firm in New Orleans, is pleased to announce the addition of attorney Frankie Cannone to its team of experienced lawyers.
  • "Cannone's unique insight into how to handle personal injury cases will be a tremendous asset to our firm," said Justin Chopin of The Chopin Law Firm.
  • The Chopin Law Firm takes a comprehensive and practical approach to personal injury law .